n | cyclic GMP (pmol/g tissue) | −cyclic GMP / +cyclic GMP (pmol PO4/min/mg protein) | PKG Activity Ratio | Relaxation (%) | |
---|---|---|---|---|---|
Control | 4 | 1.0 ± 0.02 | 13 ± 4 / 120 ± 27 | 0.11 ± 0.02 | — |
NTG (0.01 μM) | 4 | 1.1 ± 0.2 | 22 ± 3 / 147 ± 14 | 0.15 ± 0.02 | 27 ± 8* |
Control | 5 | 1.04 ± 0.15 | 13 ± 5 / 121 ± 27 | 0.11 ± 0.02 | — |
NTG (0.1 μM) | 5 | 2.7 ± 0.3* | 23 ± 6 / 123 ± 25 | 0.19 ± 0.03* | 64 ± 6* |
Control | 4 | 1.04 ± 0.15 | 15 ± 4 / 142 ± 21 | 0.10 ± 0.02 | — |
NTG (1.0 μM) | 4 | 5.4 ± 1.4* | 31 ± 5* / 122 ± 22 | 0.26 ± 0.03* | 71 ± 2* |
Control | 9 | 1.6 ± 0.4 | 21 ± 4 / 142 ± 15 | 0.14 ± 0.01 | — |
NTG (10.0 μM) | 9 | 11.2 ± 1.6* | 40 ± 2* / 150 ± 18 | 0.29 ± 0.02* | 74 ± 4* |
Values are mean ± S.E.M. NTG-treated strips were exposed to NTG for 2 min each. Means were compared with their controls by using a paired Student’s t test. * Significantly different from PE control (P < .05).